Primary immunodeficiency diseases (PI) are a group of more than 300 rare, chronic disorders in which part of the body's immune system is missing or functions improperly.
An immune deficiency disease
Primary immunodeficiencies are disorders in which part of the body’s immune system is missing or does not function normally. To be considered a primary immunodeficiency, the cause of the immune deficiency must not be secondary in nature (i.e., caused by other disease, drug treatment, or environmental exposure to toxins). Most primary immunodeficiencies are genetic disorders; the majority are diagnosed in children under the age of one, although milder forms may not be recognized until adulthood. While there are over 100 recognized PIDs, most are very rare. About 1 in 500 people in the United States are born with a primary immunodeficiency. Immune deficiencies can result in persistent or recurring infections, autoinflammatory disorders, tumors, and disorders of various organs. There are currently no cures for these conditions; treatment is palliative and consists of managing infections and boosting the immune system.
The precise symptoms of a primary immunodeficiency depend on the type of defect. Generally, the symptoms and signs that lead to the diagnosis of an immunodeficiency include recurrent or persistent infections or developmental delay as a result of infection. Particular organ problems (e.g. diseases involving the skin, heart, facial development and skeletal system) may be present in certain conditions. Others predispose to autoimmune disease, where the immune system attacks the body’s own tissues, or tumours (sometimes specific forms of cancer, such as lymphoma). The nature of the infections, as well as the additional features, may provide clues as to the exact nature of the immune defect.
The basic tests performed when an immunodeficiency is suspected should include a full blood count (including accurate lymphocyte and granulocyte counts) and immunoglobulin levels (the three most important types of antibodies: IgG, IgA and IgM).
Other tests are performed depending on the suspected disorder:
• Quantification of the different types of mononuclear cells in the blood (i.e. lymphocytes and monocytes): different groups of T lymphocytes (dependent on their cell surface markers, e.g. CD4+, CD8+, CD3+, TCRαβ and TCRγδ), groups of B lymphocytes (CD19, CD20, CD21 and Immunoglobulin), natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 (B cells).
• Tests for T cell function: skin tests for delayed-type hypersensitivity, cell responses to mitogens and allogeneic cells, cytokine production by cells
• Tests for B cell function: antibodies to routine immunisations and commonly acquired infections, quantification of IgG subclasses
• Tests for phagocyte function: reduction of nitro blue tetrazolium chloride, assays of chemotaxis, bactericidal activity.
Due to the rarity of many primary immunodeficiencies, many of the above tests are highly specialised and tend to be performed in research laboratories.
Criteria for diagnosis were agreed in 1999. For instance, an antibody deficiency can be diagnosed in the presence of low immunoglobulins, recurrent infections and failure of the development of antibodies on exposure to antigens. The 1999 criteria also distinguish between “definitive”, “probable” and “possible” in the diagnosis of primary immunodeficiency. “Definitive” diagnosis is made when it is likely that in 20 years, the patient has a >98% chance of the same diagnosis being made; this level of diagnosis is achievable with the detection of a genetic mutation or very specific circumstantial abnormalities. “Probable” diagnosis is made when no genetic diagnosis can be made, but the patient has all other characteristics of a particular disease; the chance of the same diagnosis being made 20 years later is estimated to be 85-97%. Finally, a “possible” diagnosis is made when the patient has only some of the characteristics of a disease are present, but not all.
The International Union of Immunological Societies recognizes nine classes of primary immunodeficiencies, totaling over 120 conditions. A 2014 update of the classification guide added a 9th category and added 30 new gene defects from the prior 2009 version.
We believe Infeperium breakthrough therapies to be a new category of drug that may be characterized as a Biological Response Modifier and an “Immunomodulator.” We believe that many disease pathologies that affect individuals are the result of an over-active immune system. Specifically, when a viral agent begins to adversely affect an individual’s cells, the immune system frequently becomes overactive, which destroys the viral agent but also injures surrounding healthy cell structures. We believe other disease pathologies suppress an individual’s immune system, which allows other diseases and agents to kill healthy cells.
Although research is always ongoing, the product in its present form is complete. Research has concluded that Infeperium breakthrough therapies regulate the bodies immune system to prevent it from both over-reacting and under-reacting to a viral invasion of an individual’s body systems. We believe that Infeperium breakthrough therapies contains a number of unique peptide or lipopeptide molecules which may neutralize viral pathogens and their inhibitory properties by activation of a cytokine system. This, in turn, will enhance an individual’s cell mediated immunity and augment the individual’s humoral immune system possibly by eliminating negative inhibitory cytokine factors and pathogenic free-floating organisms, while simultaneously sparing normal and healthy cells.
Preserving Acute inflammation which is necessary for healing, restoration and defense against invading pathogens.Reducing Chronic inflammation which is the beginning of the reversal of degenerative disease.
II. Restores proper Cell Signaling
Through cytokines, cell messenger pathways, cellular communication and transduction.Reverses aberrant, dysregulated, disrupted, error altered, confused and distracted communication.
III. Acts as an Adjuvants or Adjunct
Help regulate and restore the proper on/off switches of immune cascade proteins and cell activity, especially Apoptosis (programmed cell death).This will amplified proper cell activity, messaging and signal routing.
Infeperium is only available for treatment in Mexico.